GHRS · GH Research

The thesis

GH Research's shares are more likely to lag the S&P 500 over the next three months. The shares trade just above the $18.00 price of the April 2026 equity offering, and the company has not confirmed a date to start the pivotal trial of its inhaled depression drug GH001. The third-quarter 2026 report, estimated by StockAnalysis for 20 November 2026, is the next check on whether a 2026 start holds with a design the US Food and Drug Administration (FDA) has agreed.

The shares closed at $18.49 on 12 November 2026, down from $19.25 on 11 November 2026 and $19.56 on 10 November 2026. That is 41.2% below the 52-week intraday high of $31.44 set on 7 August 2026, and 37.3% lower over three months from the $29.49 close of 14 August 2026. The close sits under the 50-day average of closes ($22.48) and the 200-day average ($21.68).

The takeover premium that followed Lilly's purchase of AtaiBeckley (completed 11 September 2026) has gone. The clinical record since the company's 6 August 2026 second-quarter release has not changed, so the next new fact comes from the third-quarter report.

Bullish and bearish views on GH Research PLC

The bull case on GH Research PLC (GHRS), in brief: Phase 2b efficacy data are strong. The bear case: the takeover premium has gone.

Bull case

• Phase 2b efficacy data are strong. The company's 14 May 2026 first-quarter release cited 57.5% remission at Day 8 and 73% at six months in the GH001 Phase 2b trial in treatment-resistant depression. The results were published in JAMA Psychiatry on 25 March 2026.
• Regulatory obstacles have narrowed. The FDA lifted its clinical hold on GH001 in January 2026. The 6 August 2026 release said July FDA written feedback found the chemistry, manufacturing and controls and device plans Phase 3 ready, and that pivotal doses were selected.
• Cash funds the pivotal trial. Cash, equivalents and marketable securities were $362.7 million at 30 June 2026, after a $117.5 million underwritten offering priced at $18.00 per share on 29 April 2026.
• A large drugmaker paid for the mechanism. Lilly agreed on 16 July 2026 to buy AtaiBeckley, whose BPL-003 is also a 5-MeO-DMT depression drug, and announced completion on 11 September 2026.
• Analysts remain far above the price. StockAnalysis showed a Strong Buy consensus from 10 analysts and an average 12-month target of $42.89 on 6 November 2026.

Bear case

• The takeover premium has gone. The shares closed at $18.49 on 12 November 2026, against roughly $26 around Lilly's 16 July 2026 announcement. No second large-company deal for a psychedelic depression asset has been announced.
• The decline has no disclosed cause. Shares closed at $23.48 on 30 September 2026 and $18.85 on 13 October 2026 with no company release in between. The 12 November 2026 close is below the 9 November 2026 close of $19.26.
• The trial start has no date. The company guides only to starting the global pivotal program in 2026, and design talks with the FDA were still continuing at 6 August 2026.
• Spending is rising. The second-quarter 2026 net loss was $15.1 million ($0.23 per share), against $9.3 million a year earlier, before any pivotal patient is enrolled (6 August 2026 release).
• Dilution has a precedent. The April 2026 offering priced at $18.00 per share. Another raise before pivotal data would repeat that pattern at a price near today's.

Price setup

The shares closed at $18.49 on 12 November 2026. The 52-week closing low is $12.48, set on 15 December 2025, and the 52-week intraday high is $31.44, set on 7 August 2026.

The 5 November 2026 close of $18.44 is the lowest of the recent sessions listed. The 10 November 2026 close of $19.56 is the highest of the same stretch, and the shares gave back part of that move on 11 November 2026 and 12 November 2026.

The 50-day average of closes is $22.48 and the 200-day average is $21.68, both as of 12 November 2026. The shares sit below both. A recovery over those averages would be the first price evidence of the shares leading.

The $18.00 offering price of 29 April 2026 is the nearest reference level below the shares.

Catalysts ahead

• ~20 November 2026 (est.): Third-quarter 2026 results and business update; date not confirmed by the company. First check on whether the 2026 pivotal-start target holds with an FDA-agreed design, and on cash spent against the $362.7 million reported at 30 June 2026.
• ~31 December 2026 (est.): End of the company's guided window to start the global GH001 pivotal trial in treatment-resistant depression. A start with an FDA-agreed design is the main company-specific event that lowers risk; missing the window pushes the program into 2027.

What would change the view

A daily close above $22.67, over both the 50-day and 200-day averages of closes, which would show the shares leading the S&P 500. A company-confirmed start of the GH001 pivotal trial with an FDA-agreed design would also show the case failing.

What it trades with

GH Research traded with other psychedelic-medicine names on 20 April 2026, when the White House executive order on accelerating psychedelic drug research lifted the group. Lilly's AtaiBeckley deal on 16 July 2026 was the other sector-wide move. The drop from 30 September to 13 October 2026 came with no company news, so no single peer event explains it. The shares otherwise move with clinical-stage biotech funding conditions rather than with quarterly financials.